Evidence map›Paper›PMID 31816127›Full record

ArticleJournal of veterinary internal medicine2020

Clinical features and outcome in 25 dogs with respiratory-associated pulmonary hypertension treated with sildenafil.

Lynelle R Johnson, Joshua A Stern

Open access · goldAbstract readClinical Trial, Veterinary
In one paragraph

Article in Journal of veterinary internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Role of Personalized Medicine in Companion Animal Cardiology.The Veterinary clinics of North America. Small animal practice · 2023
    Review
  6. Article
  7. Article
  8. A dog presenting with syncope due to two different etiologies.Journal of advanced veterinary and animal research · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lynelle R JohnsonDepartment of Medicine and Epidemiology, University of California, Davis, Davis, California.ORCID https://orcid.org/0000-0002-5331-5626
Joshua A SternDepartment of Medicine and Epidemiology, University of California, Davis, Davis, California.ORCID https://orcid.org/0000-0001-5611-5745
University of California, Davis · US

Funding

American Kennel Club Canine Health Foundation 01982Bailey Wrigley FundUC Davis Center for Companion Animal Health
6 · The paper itself

Abstract

backgroundPulmonary hypertension (PH) can develop secondary to many common cardiopulmonary diseases, and the use of sildenafil has improved care of affected dogs.

objectiveTo evaluate response to sildenafil in dogs with respiratory-associated PH. ANIMALS: Twenty-five dogs with PH.

methodsProspective clinical trial. Doppler echocardiography identified dogs with moderate to severe PH, and additional tests were performed to detect underlying diseases. A 17-point quality of life (QOL) questionnaire was completed, and sildenafil was prescribed, along with other medications deemed necessary for the management of clinically diagnosed respiratory diseases. After 30 days, dogs returned to the hospital for repeat echocardiogram and QOL survey.

resultsThe median age was 12.4 years, and most dogs were small breed dogs (median weight, 6.5 kg). Syncope (64%), cough (56%), and respiratory difficulty (32%) were the most common presenting complaints. Respiratory diseases associated with PH included tracheobronchomalacia, pulmonary fibrosis, inflammatory airway disease, and brachycephalic syndrome, with multiple diseases in some dogs. Eight of 25 dogs (32%) died or were euthanized within 1 month. In the remaining dogs, tricuspid regurgitation pressure gradient (83.0 ± 17.4 mm Hg before, 55.4 ± 17.4 mm Hg after) and QOL scores were significantly improved after 1 month of sildenafil. Fifty percent mortality was reached 6 months after study entry, with 4 dogs alive 5 years after diagnosis. CONCLUSIONS AND CLINICAL IMPORTANCE: Sildenafil responsiveness is variable in dogs with respiratory-associated PH, but improved QOL was demonstrated in dogs surviving >1 month, and long-term survival was noted in some cases.

Indexed as

AnimalsDog DiseasesDogsFemaleHypertension, PulmonaryLung DiseasesMaleQuality of LifeSildenafil CitrateSurvival AnalysisTreatment OutcomeVasodilator AgentsSildenafil CitrateVasodilator Agentschronic bronchitisinterstitial lung diseasetracheobronchomalacia

Identifiers

PMID31816127
PMCPMC6979098
OpenAlexW2994206925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.